Introduction
The European e-Health Action Plan calls for interoperability between different health computer systems so that international data can be collected on the quality of care and for research. 1 Translational Research and Patient Safety in Europe (TRANSFoRm) is a European Union (EU)-funded international research project aimed at delivering part of this agenda. 2 The aim of TRANSFoRm is to bring together existing primary care databases with genetic and/or cancer registry data repositories. These linked data sets can then be used to conduct more sophisticated translational and biomedical research.
These three data sources, genetic data often in biobanks, cancer registries and routinely collected primary care data, have been widely used for research, but are rarely combined. Genetic data have been increasingly collected into biobanks since completion of the mapping of the human genome between 2001 and 2004; 3, 4 although biological specimens have been used for a longer period in pathology and forensic science. 5, 6 Cancer registries have been in place for some years 7, 8 and more recently have become international with the aim of understanding the epidemiology of conditions, 9 as well as the effectiveness of treatments. 10 Primary care clinical recording in the UK has shifted decisively from paper to computer over recent years 11, 12 with routine data widely used for research, 13 but with relatively little linkage of data beyond often disease-specific programmes in individual localities.
A central component of the TRANSFoRm project is the development of three-dimensional use-cases in two clinical domains: type 2 diabetes and gastrooesophageal reflux disease (GORD). An epidemiological study of people with type 2 diabetes aspires to link genetic and primary care data sets and set outs to explore the risk of complications and responses to oral medications. In the GORD domain there are two use-cases. The first is a case-controlled study of the association of GORD symptoms and the use of acidblocking drugs (specifically proton pump inhibitors; PPIs) with developing Barrett's disease and cancer of the oesophagus. The second is a randomised controlled trial of on-demand compared with continuous PPI drug use, including monitoring patients' symptoms and outcomes.
We set out to develop a survey instrument that could determine if a database was able to meet the requirements analysis and participate in linked data research projects as set out in these use-cases.
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Method Overview
We report the development of a survey instrument to collect the data identified in our requirements analysis. 14, 15 In brief, this was part of the TRANSFoRm project, whose relevant work tasks are summarised in Table 1 . Our requirements analysis identified data requirements at the micro-, meso-and macro levels, study-specific requirements and proposed that the research track record was used as a sensitivity analysis (Figure 1) . Functionally, our micro-requirements describe potential study data quality 16 and its readiness to incorporate into linked research; the mesolevel items to the technical readiness of the system and data export systems. Key among the macrosociocultural issues are governance and regulatory readiness, without which it is not possible to proceed. Study-specific information, driven by the nature of the data held and the sample size required to flag readiness for a particular study.
We adopted a two-phase approach to determine the capability of primary care data repositories to link to genotype data repositories and disease registries. Phase one was the development of the survey instrument reported here, and phase two was data collection and analysis.
TIRRE questionnaire content
We created a framework for the data needed to assess the fitness and preparedness of repositories to participate in linked research. The framework drew on principles from interoperability, EPR architecture, modelling and existing research data schema. Using this framework, we developed a questionnaire that could be used to collect data through a telephone survey or be self-administered online. The framework ensured that the survey data were collected at three levels of granularity using standard headings for each section of the questionnaire; additionally collecting the study-specific data. The heterogeneity of the data meant that we needed to extract comprehensive information about the data and how it was structured. The first section, the micro level was concerned with the data source, the data itself, metadata, the potential for linkage or achieving semantic interoperability between data sources, 17 and details of how many studies have been published using the data. The second section, the meso level, explored data extraction, 18 the architecture of the computerised medical record Using the results of the EHR capacity study within the EGPRN and ESPCG networks (WT1.1) we will conduct an in-depth study of the most common EHR systems used in Europe to examine the availability of API details. The scope of the study will include patient held records, which may hold substantially less coded and structured data. These will include Microsoft and Google patient record systems -and countries where health cards are used.
2.
We will conduct a parallel in-depth study of data repositories that can be used for clinical trials. We will look to identify local, EHR brand-specific and health-system access points to primary care data. The types of data access points we might be able to run queries on include:
(1) billing or performance indicator extracts of routine data; (2) sentinel networks or research network database; and (3) national data extract systems with closed API. These may provide pragmatic quick win access to primary care data while a longer term access is being developed.
WT 6.2: Requirements analysis of genotype data repositories
We will conduct a parallel in-depth study of (genotype) clinical data repositories across Europe and their potential use for clinical research. The scope of the study will include structured genotype data and potential integration points with patient health care for biomedical and translational clinical research. Genotype data is normally held by biobanks or other research organisations either as sample identification information or specific codes for single nucleotide polymorphisms (SNPs).
(CMR) and other data repositories, 19 audit trails and the size of the database. Finally, the third section, the macro level, explored issues relating to the nature of the health system, sociocultural factors and issues relating to funding, the purpose and restrictions on the use of the data. Study-specific questions make up the final part of the survey instrument (Figure 1) . 20 Piloting the TIRRE questionnaire with the first ten repositories
We initially contacted 10 sites who were interested in participating in the TRANSFoRm project by email, if available, and followed this up with telephone calls. We collected data through a structured telephone interview. These 10 repositories were based throughout Europe. These first 10 sites were also stakeholders in our requirements analysis. 18 The pilot sample
The pilot sample was comprised of mainly primary care databases (50%, n = 5); this was principally because we had better links to these databases and this made conducting the telephone pilot easier. The sample included epidemiological cohorts (20%, n = 2), disease registries (20%, n = 2) and a genomic database (10%, n = 1). All of the organisations questioned held data for the purpose of research. We set out to recruit a representative sample.
Development of the online questionnaire using skip logic
We then developed and introduced an online version of our survey instrument whilst continuing to offer the telephone method in parallel for repositories that preferred to pass on information this way. The survey was comprehensive and consisted of 160 questions. We used a software package from SurveyMonkey TM to create and develop the online questionnaire. To avoid Figure 1 Detail of the questionnaire schema. At the data-source level, A is completed by genetic databases only unnecessary repetition in data collection and to ensure that only relevant information for each type of repository was collected, the online version was designed using skip logic. Skip logic also has the benefit of making the survey instrument more streamline, reducing the number of questions each respondent is required to answer (Table 2 ).
Ethical considerations
There was no formal ethics board review. This survey only seeks to report information about the capacity and capability of information sources to be combined to conduct research studies. The survey does include a self-declaration that the data held were subject to an ethical process. We did not consider any issues of consent or privacy, beyond exploring a site's track record for studies and that there was a mechanism for obtaining consent for any specific study.
Results
The pilot sample Seven of the ten sites confirmed that there were no restrictions on the use of their data for ethically approved research studies and all had had studies completed and published using their data source.
Seven were able to confirm that their data sets could be used for cross-sectional studies, three had the ability to link to other genetic databases and three had access to other methods of data collection such as social security systems. Five of the repositories required additional patient consent to be completed to use their data for research; of these, four confirmed that individual consent was not required if strong identifiers were removed. The same five stated that individual consent was required to: (1) link single nucleotide polymorphisms (SNPs) to phenotype or primary care data studies, and (2) identify individuals participating in cohort, cross-sectional studies or for recruitment into trials. Eight repositories were able to confirm that there was a local or network-specific protocol for ethical approval that needed to be followed for their collections, and seven said that there were restrictions on the use of their data for ethically approved research studies. Seven of the repositories confirmed their data source did not employ a unique identifier to allow linkage between primary care, hospital and national health data. The majority held historical data (e.g. from a patient's birth) and all except one could provide age-sex profile data from their source.
The sample was drawn as follows: there were five primary care sites, one from each of France, Germany, Denmark, Italy and Finland. France also provided two epidemiological cohorts; there was a genomics database from the UK and a disease registry from Switzerland completed the sample. 
Feedback and developing the questionnaire
The initial telephone interview took around 1.5 hours to complete. This was deemed too long, felt onerous for the person supplying the information and provided no obvious benefit to them. With this in mind, we sought to improve the questionnaire by three methods. First, we analysed the 104 questions that had a yes/no response and explored whether they are more likely to be positive in a database that is eligible to complete the use-case. Second, we looked at the multiple response questions, simplifying them into single response questions, we looked for common categories that allowed us to reduce the number of free-text responses and investigated the skip logic sections. Third, we removed questions that did not discriminate between use-case eligible or not. The study team then reviewed questions for potential removal from the TIRRE survey instrument, as some non-discriminatory data may still be useful and required (e.g. all databases need to be able to state the size of their population). As a result of the above activities, we have been able to remove the questions that we do not think are essential, reducing the number to 139. For the second version of the TIRRE survey instrument we removed 'Don't know' as an answer option in order to prompt a yes or no response. Many questions from the first version of the TIRRE survey were combined and rewritten for the second version in order to simplify answer options.
To improve the identification of data sources with greater potential for generating linkages we added a new Question 4 'Does the data source provide national coverage?', and to assess the readiness of a data source to participate in a specific study we added new questions 'From first receiving a formal request for study data, how long do you anticipate it would take you to export the data to researchers?' (Question 136 in TIRRE2) and 'In the last 12 months what is the mean time taken from receiving any formal request for study data through to exporting that data to researchers?' (Question 137 in TIRRE2). We removed Questions 33-36 (asking for text data about the actual publications) as we felt this data could be asked for or checked subsequently if necessary. In order to simplify the responses we rewrote many questions. For example, we changed Question 38 (the original Question 42 in TIRRE1) from 'How long does it typically take to get ethical approval?' to 'Does it typically take less than 6 months to get ethical approval'. This process is subject to on-going development.
Summary results
We created a screening tool to assess the readiness of clinical data repositories around the world to participate in linked research. By utilising skip logic we can streamline the TIRRE tool, making it more specific to each type of stakeholder and reducing the number of questions needed (Tables 3 and 4) . Questions selected for the final online version were judged to be essential to ascertain key information about the suitability of data repositories from at least two members of the same group.
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Sensitivity analysis
Eight of the ten data-providing stakeholders could quote peer review publications produced from their data and indexed in PubMed. 23 Four estimated that between 30 and 100 peer review articles had been published in the last five years; of the remaining six, two estimated that between 11 and 20 articles had been published, one estimated that 2 to 5 articles had been published, and one stated that no publications had been generated based on their data. 
Discussion Principal findings
The TIRRE instrument is a screening tool to assess both the potential of a database to take part in usecases and the feasibility of conducting linked research; although we recognise that further testing may be required before a data source participates in a study. The TIRRE survey systematically collects the extensive amount of information required to assess readiness to participate in studies linking primary care and either genetic databases or cancer registry data. It is based on a requirements analysis. Although we had difficulty in getting databases to complete the questionnaire, when we did get a response the completeness of the information gathered was high and proved useful in identifying their potential to participate in linked research. There are currently no other international sites available to enable brokerage between databases willing to participate in research.
Implications of the findings
The TIRRE survey is the best first step towards assessing the 'linkability' of databases in one locality and the extent to which a study might be run across several localities. It has the potential to measure readiness in several dimensions:
. data quality readiness from micro-level information . record readiness and the technical ability of the computer systems that hold the data to export it reliably and . governance readiness, including any information about sociocultural barriers to utilisation.
Collectively, these dimensions inform about the readiness to scale the study beyond a single databasewhich we term scalability readiness. However, any initial screening process may need to be followed up by a detailed assessment of whether the data set needed for a given study can be elicited from the data repositories. 25 and other sentinel networks all follow the same pattern. Even the relatively simple task of linking data from this small number of brands of computer within the UK has proved challenging, in terms of both creating a summary care record 26 and developing a common dataextraction system. 27 Overall, we are unable to find anything similar to TRANSFoRm in academia. Wider use of ontologies may provide a framework for better information sharing. 28, 29 Little has been written about the concept of research readiness and its importance for studies requiring data from more than one source. Early conceptual models for primary care research networks focused on the structures, process and outcomes -without thinking of readiness as a key concept. 30 Research readiness has been introduced in the UK at the individual practice level; although this is through a system of selfaccreditation. 31 Internationally, the Electronic Health Record for Clinical Research (EHRCR) Project has produced a functionality profile which outlines the high-level requirements necessary for EHR systems to be considered as a reliable data source in line with the appropriate regulations governing clinical research. This profile will be used as the basis for the certification of EHR systems used in clinical research with the aim of increasing the level of comfort of practitioners, the research community and regulators with the practice of storing source data in EHR systems; 32 although this approach does not appear to have been adopted widely.
Limitations of the method
An initial survey, provided from a previous work package, provided limited information on the suitability and readiness of databases. 17 Redefinition of the variables required for these databases enabled us to conduct a further survey. There was no real incentive for data repositories to supply us with the data required, as there was not a reciprocal offer of benefit. Successful completion of the survey was a lengthy process, taking in excess of 1 hour. As a consequence, our results inevitably underestimate the number of sites where this type of research can be conducted.
Inevitably, simplification needed to construct effective middleware. The use-cases have developed appropriate but complex models. The provenance of data defined within the work package has been broad, seeking to map the provenance of data from the original observation, but going beyond the scope of the study use-cases.
Finally, our approach was framed by the English context, 33 and communication in English. However, in mitigation we also have a European perspective on health system data. 34 
Call for further research
We need to conduct test-retest studies to assess the reliability of the survey instrument. We should conduct simulated and real studies with data extractions to test its validity.
Conclusions
A large complex set of data is needed to know if it will be possible to link primary care and either a disease registry or genetic database. This set of data can either be classified by the level of granularity or as a business or data requirement. The TIRRE instrument is evolving into a tool that can be used to assess general suitability and readiness to participate in linked research studies.
